Novocure Ltd Stock
€15.12
Your prediction
Novocure Ltd Stock
Pros and Cons of Novocure Ltd in the next few years
Pros
Cons
Performance of Novocure Ltd vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Novocure Ltd | -0.850% | 5.331% | -10.217% | -8.227% | -48.094% | -77.223% | -71.373% |
Ironwood Pharmaceuticals | 1.690% | 4.202% | 12.727% | -89.217% | -85.238% | -94.341% | -93.111% |
Arrowhead Pharmaceuticals Inc. | -1.010% | 0.075% | -5.125% | -44.637% | -27.440% | -60.048% | -65.061% |
Iovance Biotherapeutics Inc. | 4.140% | -9.099% | -5.739% | -80.618% | -79.024% | -86.246% | -94.076% |
News

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable

Novocure to Report Second Quarter 2025 Financial Results
Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society